Descartes-15
/ Cartesian Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 10
Of
10
Go to page
1
November 25, 2025
DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=4 | Terminated | Sponsor: Cartesian Therapeutics | Trial completion date: Oct 2027 ➔ Nov 2025 | Active, not recruiting ➔ Terminated | Trial primary completion date: Dec 2026 ➔ Apr 2025; Phase 1 enrollment completed. Further clinical development terminated
Trial completion date • Trial primary completion date • Trial termination • Hematological Malignancies • Multiple Myeloma • Oncology
November 06, 2025
First-in-Human Phase 1 Clinical Trial of Descartes-15 Remains Ongoing
(GlobeNewswire)
- "The Phase 1 dose escalation trial of Cartesian’s next-generation, autologous anti-BCMA CAR-T cell therapy is designed to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma."
Enrollment status • Multiple Myeloma
November 13, 2025
Preliminary Descartes-15 Safety Data
(GlobeNewswire)
- "The Company today reported results from the Phase 1 dose escalation trial designed to assess safety and tolerability of outpatient administration of Descartes-15 in patients with multiple myeloma. In this trial, no significant adverse events or dose-limiting toxicities were reported in any participants (n=3). The only Descartes-15-related adverse event was a grade 2 hypotension occurring after the first two infusions. Despite favorable safety data now in hand, Cartesian plans to pause the development of Descartes-15 to prioritize opportunities for Descartes-08..."
Discontinued • P1 data • Multiple Myeloma
May 30, 2025
DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=4 | Active, not recruiting | Sponsor: Cartesian Therapeutics | Recruiting ➔ Active, not recruiting | N=41 ➔ 4
Enrollment change • Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology
May 08, 2025
Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
(GlobeNewswire)
- "Dosing Continues in First-in-Human Phase 1 Clinical Trial of Descartes-15. The Phase 1 dose escalation trial of Cartesian’s next-generation, autologous anti-BCMA CAR-T cell therapy, is designed to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. Following the Phase 1 dose escalation trial, the Company expects to subsequently assess Descartes-15 in autoimmune indications."
Trial status • Immunology • Multiple Myeloma
September 03, 2024
Cartesian Therapeutics Announces First Patient Dosed in First-In-Human Phase 1 Trial of Next-Generation mRNA CAR-T Cell Therapy Descartes-15
(GlobeNewswire)
- "Cartesian Therapeutics, Inc...announced that the first patient has been dosed in its first-in-human Phase 1 trial of Descartes-15, the Company’s next-generation autologous anti-B cell maturation antigen (BCMA) mRNA-engineered chimeric antigen receptor T-cell therapy (mRNA CAR-T)....The Phase 1 dose escalation trial (NCT06304636) will assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma."
Trial status • Hematological Malignancies • Multiple Myeloma • Oncology
August 08, 2024
Cartesian Therapeutics Announces $130 Million Private Placement Equity Financing
(GlobeNewswire)
- "Descartes-08 for Pediatric Autoimmune Diseases: Cartesian plans to file an Investigational New Drug (IND) application for Descartes-08 in pediatric autoimmune disease indications by year-end 2024....Descartes-15 for Autoimmune Diseases: The Company expects to dose the first patient in its planned Phase 1 trial of Descartes-15 in the second half of 2024.....Completed $130 Million Private Placement Equity Financing...Cartesian announced a private investment in public equity (PIPE) financing, which included participation from both new and existing investors, resulting in gross proceeds of approximately $130.0 million....Cartesian expects to use the net proceeds to advance and expand its autoimmune pipeline through continued development of Descartes-08 for SLE, Descartes-15 for autoimmune diseases."
Financing • IND • New P1 trial • Immunology
June 13, 2024
DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=41 | Recruiting | Sponsor: Cartesian Therapeutics | Initiation date: Mar 2024 ➔ Jun 2024
Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology
March 12, 2024
DC15-MM-01: Descartes-15 for Patients With Relapsed/Refractory Multiple Myeloma
(clinicaltrials.gov)
- P1 | N=41 | Recruiting | Sponsor: Cartesian Therapeutics
New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology
January 08, 2024
Cartesian Therapeutics Highlights Progress and 2024 Strategic Priorities Across Innovative Pipeline of mRNA Cell Therapies for Autoimmunity
(GlobeNewswire)
- "Program Updates and Anticipated 2024 Milestones....The Company today announced that the U.S. FDA has cleared its IND application for Descartes-15. Planning for a first-in-human Phase 1 dose escalation study is underway. The study will be designed to assess the safety and tolerability of outpatient Descartes-15 administration in patients with multiple myeloma. The Company expects to subsequently assess Descartes-15 in autoimmune indications."
IND • New P1 trial • Hematological Malignancies • Immunology • Multiple Myeloma • Oncology
1 to 10
Of
10
Go to page
1